Difference between revisions of "Ipilimumab (Yervoy)"
m |
|||
| Line 1: | Line 1: | ||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Anti-CTLA-4 antibody. CTLA-4 is a negative regulator of T-cell activation and ipilimumab interferes with the ability of CTLA-4 to interact with its ligands CD80/CD86. CTLA-4 blockade results in T-cell activation and proliferation, and it is suspected that its anti-neoplastic activity may be due to T-cell mediated anti-tumor immune responses.<ref name="insert">[http://packageinserts.bms.com/pi/pi_yervoy.pdf Ipilimumab (Yervoy) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/ipilimumab.pdf Ipilimumab (Yervoy) package insert (locally hosted backup)]</ref> | Class/mechanism: Anti-CTLA-4 antibody. CTLA-4 is a negative regulator of T-cell activation and ipilimumab interferes with the ability of CTLA-4 to interact with its ligands CD80/CD86. CTLA-4 blockade results in T-cell activation and proliferation, and it is suspected that its anti-neoplastic activity may be due to T-cell mediated anti-tumor immune responses.<ref name="insert">[http://packageinserts.bms.com/pi/pi_yervoy.pdf Ipilimumab (Yervoy) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/ipilimumab.pdf Ipilimumab (Yervoy) package insert (locally hosted backup)]</ref> | ||
| Line 10: | Line 9: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://www.uptodate.com/contents/ipilimumab-patient-drug-information Ipilimumab (Yervoy) patient drug information (UpToDate)]<ref>[ | + | *[http://www.uptodate.com/contents/ipilimumab-patient-drug-information Ipilimumab (Yervoy) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ipilimumab-patient-drug-information Ipilimumab (Yervoy) patient drug information (UpToDate)]</ref> |
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 03:02, 14 March 2012
General information
Class/mechanism: Anti-CTLA-4 antibody. CTLA-4 is a negative regulator of T-cell activation and ipilimumab interferes with the ability of CTLA-4 to interact with its ligands CD80/CD86. CTLA-4 blockade results in T-cell activation and proliferation, and it is suspected that its anti-neoplastic activity may be due to T-cell mediated anti-tumor immune responses.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].